SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline (JOBS) Temporarily Withdraws Avodart Cancer Filing

November 23, 2009 | 
1 min read

Bookmark and Share

Reuters -- GlaxoSmithKline temporarily withdrew its application to U.S. regulators for a new use of its Avodart drug in preventing prostate cancer because of a technical problem with the file, it said on Monday.

Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
February 3, 2025
 · 
3 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: GSK, Indivior, SpringWorks, More
February 3, 2025
 · 
5 min read
 · 
Tristan Manalac
Profile view, and Mental Illness
Approvals
Axsome’s Migraine Medicine Clears FDA Bar
January 31, 2025
 · 
2 min read
 · 
Tristan Manalac